Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428643 | 0.86 | NPC1 (0.45) | CHRM1HPGDRAB9ANPC1P2RX7 | |
| SCHEMBL6390194 | 0.86 | NPC1 (0.45) | CHRM1HPGDRAB9ANPC1P2RX7 | |
| SCHEMBL6394209 | 0.80 | RAB9A (0.43) | HPGDRAB9ANPC1P2RX7TDP1 | |
| SCHEMBL6393301 | 0.80 | RAB9A (0.43) | HPGDRAB9ANPC1P2RX7TDP1 | |
| SCHEMBL6390207 | 0.80 | RAB9A (0.43) | HPGDRAB9ANPC1P2RX7TDP1 | |
| SCHEMBL6504984 | 0.77 | SMN1; SMN2 (0.44) | HPGDRAB9ANPC1P2RX7 | |
| SCHEMBL6388874 | 0.77 | SMN1; SMN2 (0.44) | HPGDRAB9ANPC1P2RX7 | |
| SCHEMBL6387573 | 0.77 | SMN1; SMN2 (0.44) | HPGDRAB9ANPC1P2RX7 | |
| SCHEMBL6505267 | 0.77 | ATM (0.41) | RAB9ANPC1ATM | |
| SCHEMBL6426489 | 0.76 | P2RX7 (0.43) | RAB9ANPC1P2RX7ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | CHRM1 532/4885HPGD 66/4885RAB9A 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.